Clinical Trials

MainTitle

Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers (Darifi)

This study has been terminated
( Risks to participation )

Sponsor
University of Cape Town

Collaborator
Wits Reproductive Health and HIV Institute
Desmond Tutu HIV Centre

Information provided by (Responsible Party)
Helen Margaret McIlleron, University of Cape Town

ClinicalTrials.gov Identifier
NCT03892161

First received: April 23, 2018
Last updated: April 1, 2019
Last Verified: April 2019
History of Changes
Purpose

Purpose

The DaRifi study aims:

  1. Develop adjusted doses of darunavir/ritonavir for use in HIV-infected patients requiring co-treatment of TB with a rifampicin-based regimen.
  2. Compare the steady state pharmacokinetics of doubled doses of DRV/r with rifampicin (in once daily and 12-hourly approaches) to standard daily doses without rifampicin.
  3. Twenty-eight volunteers will be enrolled for a target of 24 participants completing the
study.

Condition Intervention Phase
HIV Infections

Drug : Darunavir/ritonavir 800/100 mg tablet
Drug : Rifampicin 600mg QD tablet and DTG 50mg BD
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: A phase I, open-label, cross-over, single center, PK drug-drug interaction study will be conducted in 24 medically stable HIV-1 infected adults with viral suppression (viral load <50 copies/mL).
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers

Further study details as provided by Helen Margaret McIlleron, University of Cape Town:

Primary Outcome Measures

  • Darunavir plasma concentrations nanogram per milliliter (ng/ml) [ Time Frame: 1 year ]
    Darunavir plasma concentrations will be compared with rifampicin and without rifampicin.
Secondary Outcome Measures:
  • Alanine Transaminase (ALT) blood level (iu/L) [ Time Frame: 1 Year ]
    Clinical safety will be monitored, ALT liver enzyme tests will be evaluated every 3 days.

Enrollment: 17
Study Start Date: April 12, 2018
Study Completion Date: November 22, 2018
Estimated Primary Completion Date: November 22, 2018 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Standard dose DRV/r
Standard dose DRV/r 800/100mg without Rifampicin
Drug: Darunavir/ritonavir 800/100 mg tablet

Standard dose DRV/r administered

Experimental: Standard DRV/r with Rifampicin
Rifampicin 600mg QD will be added and darunavir/ritonavir steady state pharmacokinetic analysis will be performed.
Drug: Darunavir/ritonavir 800/100 mg tablet

Standard dose DRV/r administered

Drug: Rifampicin 600mg QD tablet and DTG 50mg BD

Rifampicin and DTG added

Experimental: Boosed ritonavir 200mg
Rifampicin 600mg QD continued with ritonavir 200mg dose doubled QD and darunavir remains 800mg QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
Drug: Darunavir/ritonavir 800/100 mg tablet

Standard dose DRV/r administered

Drug: Rifampicin 600mg QD tablet and DTG 50mg BD

Rifampicin and DTG added

Experimental: Double dose DRV/r 1600/200mg QD
Rifampicin 600mg QD and DTG QD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
Drug: Darunavir/ritonavir 800/100 mg tablet

Standard dose DRV/r administered

Drug: Rifampicin 600mg QD tablet and DTG 50mg BD

Rifampicin and DTG added

Experimental: Double dose DRV/r 800/100mg BD
Rifampicin 600mg QD and DTG BD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
Drug: Darunavir/ritonavir 800/100 mg tablet

Standard dose DRV/r administered

Drug: Rifampicin 600mg QD tablet and DTG 50mg BD

Rifampicin and DTG added

Detailed Description:

A significant barrier to the use of better tolerated antiretrovirals in many low-to-middle income countries (LMIC), where tuberculosis (TB) is endemic, is a lack of evidence to support their use in patients with TB. Access to optimal protease inhibitor (PI)-based regimens for patients with and without TB is urgent. Switching rifampicin to rifabutin, a weak inducer that does not significantly reduce PI concentrations, is recommended in high income countries for patients on boosted PIs who develop TB. However, rifabutin is not available in most LMIC where TB is typically treated with fixed dose combination tablets.
We will enrol virologically suppressed participants on a second-line DRV/r regimen without TB. Based on data from a Physiologically-Based PK model, we selected two adjusted doses of DRV/r (1600/200 mg daily and 800/100 mg 12 hourly) with RIF for comparison to plasma exposures with DRV/r 800/100 mg daily without RIF, in a cross-over design.
Baseline DRV steady state PK will be determined and RIF added for 7 days, then the dose of ritonavir will be increased to 200 mg; 7 days later the dose of DRV will be increased; after another 7 days participants will be crossed over to the alternative adjusted DRV dose.
DRV will be measured in plasma samples after observed doses at baseline and after each dose adjustment. Non-compartmental analysis will be used to estimate the PK measures. Clinical adverse events, ALT, and bilirubin will be monitored every 2 to 3 days during treatment with RIF.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years to 60 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria

  • Male or female
  • Aged 18 to 60 years, inclusive
  • Weighing > 38 kg
  • BMI > 18.5 kg/m2
  • HIV-1 infected
  • HIV-1 RNA <50 copies/mL
  • CD4+ lymphocyte count > 200 cells/L
  • C-reactive protein <10 mg/L
  • Established on current ART regimen of boosted protease inhibitor plus 2 NRTIs for at least 3 months.
  • Women must be postmenopausal, surgically sterile or practicing an effective birth control method (established before and maintained throughout the trial). Women who are not sexually active must agree to use an effective birth control method if they become heterosexually active during the trial.
  • Understand the purpose of and procedures required for the study and having confirmed they are willing to participate in the study by signing the informed consent document.

  • Exclusion criteria (volunteers meeting any of the criteria will be excluded)
  • TB (confirmed or suspected)
  • Any symptoms of TB - as assessed by the WHO symptom-screening algorithm: self-reported or documented weight loss, cough, night sweats or fever.
  • Clinical or laboratory evidence of significantly impaired hepatic function, or documented hepatic cirrhosis
  • Clinical or laboratory evidence of acute viral hepatitis
  • Co-infected with HBV or HCV.
  • ALT grade 2 or higher (as defined by DAIDS grading table (ALT >2.5 x ULN)
  • DAIDS grade 3 or 4 laboratory abnormality
  • Active (not clinically stabilized >4 weeks) AIDS defining illness (Category C conditions according to the Center for Disease Control Classification System for HIV infection) with the following exceptions:
  • Stable cutaneous Kaposi's Sarcoma (no internal organ involvement other than oral lesions) that is unlikely to require any form of systemic therapy during the study.
  • Estimated creatinine clearance <50 mL/min.
  • Active clinically significant renal or gastro-intestinal disease.
  • Any active clinically significant or life-threatening disease, medical or psychiatric condition, or findings during screening, that in the investigator's opinion would compromise the safety of the participant or the study outcome, or their ability to comply with the study procedures.
  • Chronic medical requirement for any drugs that are known to affect the PK of the study drugs.
  • Active drug/alcohol abuser.
  • Pregnant or breastfeeding.
  • Increased risks of drug side effects/hypersensitivity reactions e.g. haemophilia or history of sulfonamide allergy.
  • Currently enrolled in an investigational drug study or has participated in an investigational drug study within the 4 weeks before screening.
  • Unable to comply with peri-study restrictions

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03892161

Locations

South Africa
Clinical Research Centre
Cape Town, Western Cape, South Africa, 7725

Sponsors and Collaborators

University of Cape Town
Wits Reproductive Health and HIV Institute
Desmond Tutu HIV Centre

Investigators

Principal Investigator: Helen McIlleron, PhD University of Cape Town
More Information

More Information


Responsible Party: Helen Margaret McIlleron, Professor, University of Cape Town  
ClinicalTrials.gov Identifier: NCT03892161   History of Changes  
Other Study ID Numbers: Darifi  
Study First Received: April 23, 2018  
Last Updated: April 1, 2019  
Individual Participant Data    
Plan to Share IPD: No  

Studies a U.S. FDA-regulated Drug Product: No  
Studies a U.S. FDA-regulated Device Product: No  

Additional relevant MeSH terms:
HIV Infections
Ritonavir
Darunavir
Rifampin

ClinicalTrials.gov processed this data on May 24, 2020
This information is provided by ClinicalTrials.gov.